Published in Oncologist on March 25, 2011
Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol (2016) 2.36
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Castleman disease mimicked pancreatic carcinoma: report of two cases. World J Surg Oncol (2012) 0.92
Case of autoimmune hepatitis with markedly enlarged hepatoduodenal ligament lymph nodes. World J Gastroenterol (2013) 0.90
Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep (2015) 0.83
Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev (2014) 0.80
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol (2016) 0.79
TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature. Case Rep Hematol (2016) 0.77
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol (2012) 0.77
Surgical management of isolated retroperitoneal Castleman's disease: A case report. Oncol Lett (2016) 0.75
Intrathoracic Castleman's disease: "An important clinical mimicker". Lung India (2017) 0.75
Asymptomatic Isolated Retroperitoneal Castleman's Disease: A Case Report. Iran J Med Sci (2015) 0.75
Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. J Med Case Rep (2015) 0.75
TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. Bosn J Basic Med Sci (2017) 0.75
General anesthesia in a patient with multicentric Castleman's disease: a case report. Korean J Anesthesiol (2015) 0.75
An autoinflammatory neurological disease due to interleukin 6 hypersecretion. J Neuroinflammation (2013) 0.75
Cerebral angiitis associated with subarachnoid hemorrhage in Castleman's disease: report of two cases. BMC Neurol (2016) 0.75
Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case Rep Oncol Med (2013) 0.75
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. BMC Hematol (2014) 0.75
Review of siltuximab in the treatment of multicentric Castleman's disease. Ther Adv Hematol (2016) 0.75
Castleman's disease: a rare presentation in a retroperitoneal accessory spleen, treated with a minimally invasive robotic approach. J Surg Case Rep (2017) 0.75
Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions. Intern Med (2017) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 14.33
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood (2000) 4.22
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med (2000) 4.20
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood (1989) 4.17
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem (1996) 3.57
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer (1999) 2.90
The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol (2005) 2.75
A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol (1985) 2.67
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer (2001) 2.59
The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med (1998) 2.57
Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol (1997) 2.56
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood (2003) 2.41
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest (1990) 2.37
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31
Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS (1996) 2.28
High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood (2002) 2.26
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci (2003) 2.04
Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med (1954) 1.85
Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol (1985) 1.79
Fifty years of multicentric Castleman's disease. Acta Oncol (2004) 1.65
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol (2007) 1.49
Castleman disease. Curr Opin Hematol (2007) 1.47
The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol (2009) 1.46
The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem (2003) 1.42
HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis (2008) 1.42
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine (2002) 1.34
Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol (2006) 1.33
Treatment of Castleman's disease. Curr Treat Options Oncol (2005) 1.26
Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage (2008) 1.24
Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother (1997) 1.23
Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol (1997) 1.22
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs (2008) 1.19
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
Rituximab therapy for HIV-associated Castleman disease. Blood (2003) 1.16
Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol (2009) 1.14
Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol (2009) 1.09
Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol (2005) 1.09
Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res (2004) 1.09
New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol (2008) 1.07
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood (2001) 1.05
Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant. Korean J Intern Med (2007) 1.04
Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol (1999) 1.03
Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.02
HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS (2009) 1.00
Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol (2003) 1.00
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther (2010) 1.00
Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol (1983) 1.00
Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis (2002) 0.99
An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med (1999) 0.99
Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol (2004) 0.98
Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis (2002) 0.98
[Castleman's disease]. Rev Med Interne (1996) 0.98
Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS (2008) 0.97
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol (2005) 0.96
Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease. Cancer Invest (2005) 0.95
IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol (2008) 0.95
A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol (2003) 0.94
Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res (2009) 0.94
B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood (2005) 0.94
Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res (2007) 0.91
Peripheral neuropathy associated with Castleman's disease. J Neurol Sci (1989) 0.91
Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis (2000) 0.90
Long-term complete remission after interferon treatment in a case of multicentric Castelman's disease. Am J Hematol (1995) 0.90
Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol (2006) 0.89
Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood (2004) 0.88
Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? Eur J Intern Med (2007) 0.88
Alpha-interferon in angioimmunoblastic lymphadenopathy. Ann Intern Med (1988) 0.87
Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS (2003) 0.87
Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol (2000) 0.87
Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol (2001) 0.87
Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma (2004) 0.85
Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome. Arch Pathol Lab Med (2003) 0.84
Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol (2005) 0.84
Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol (2005) 0.83
Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol (2006) 0.83
Multicentric Castleman's disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient. AIDS (2004) 0.81
Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol (1986) 0.81
Is interferon-a an active agent in Castleman's disease? Ann Oncol (1992) 0.81
Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease. Leuk Lymphoma (2008) 0.80
Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS (2003) 0.80
Castleman's disease, plasma-cell type. Diagnosis of central nervous system involvement by cerebrospinal fluid cytology. Acta Cytol (1986) 0.80
Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol (2007) 0.79
Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res (2009) 0.78
Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol (2006) 0.77
Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. Eur J Haematol (1987) 0.77
2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol (1995) 0.77
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol (2012) 2.09
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Sarcoidosis and malignancy. Clin Dermatol (2007) 1.67
Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol (2011) 1.58
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol (2008) 1.57
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma (2006) 1.55
Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol (2011) 1.54
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res (2007) 1.49
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res (2011) 1.46
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.43
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer (2009) 1.42
Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biol Ther (2009) 1.41
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res (2008) 1.41
BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma (2006) 1.40
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev (2012) 1.40
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer (2009) 1.39
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer (2011) 1.37
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood (2005) 1.34
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One (2011) 1.34
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book (2013) 1.30
PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget (2012) 1.30
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther (2007) 1.27
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res (2011) 1.26
Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther (2007) 1.26
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24
Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol (2002) 1.21
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res (2012) 1.21
Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol (2008) 1.19
Development of curcumin as an epigenetic agent. Cancer (2010) 1.18
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther (2010) 1.16
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood (2002) 1.16
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab (2009) 1.13
Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol (2008) 1.12
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol (2010) 1.12
Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol (2004) 1.11
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther (2012) 1.10
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood (2007) 1.09
Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. Clin Dermatol (2012) 1.09
Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology (2011) 1.09
Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol (2010) 1.08
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol (2011) 1.07
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res (2013) 1.06
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther (2008) 1.06
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol (2008) 1.06
Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev (2007) 1.05
The Karabus affair speaks to larger issues for American academic and medical centers. Clin Dermatol (2013) 1.05
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res (2009) 1.04
Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma (2006) 1.04
Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol (2011) 1.03
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol (2008) 1.03
Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage (2009) 1.02
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol (2010) 1.02